Novo Nordisk, Mylan Miss Views; Mallinckrodt Beats

By | August 7, 2014

Scalper1 News

Earnings reports from specialty drugmakers continued to roll in Thursday, as two leading stocks stumbled in the early going on the stock market today. Danish diabetes giant Novo Nordisk (NVO) reported Q2 profit of 2.66 kroner (42 cents) a share, up 7% from the year-earlier quarter and beating analysts’ consensus of 2.59. Sales of 21.6 billion kroner ($3.4 billion), however, were a bit shy of estimates, and up just 1% from the prior year. Novo Scalper1 News

Scalper1 News